Hemophilia A Overview

Hemophilia A, also known as classical hemophilia, is a genetic bleeding disorder caused by insufficient levels of a blood protein called factor VIII. People with hemophilia A will bleed more than normal after an injury, surgery, or dental procedure. This disorder can be severe, moderate, or mild. In severe cases, heavy bleeding occurs after minor injury or even when there is no injury.

“Hemophilia A Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia A Market.

The Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hemophilia A Pipeline Report:

• Companies across the globe are diligently working toward developing novel Hemophilia A treatment therapies with a considerable amount of success over the years. Hemophilia A Key players such as – Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceuticals, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others, are developing therapies for the Hemophilia A treatment 

• Hemophilia A Emerging therapies such as – Research program, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others are expected to have a significant impact on the Hemophilia A market in the coming years.   
• In May 2022, the US Food and Drug Administration (FDA) lifted a clinical hold on the Phase III trial testing the safety and effectiveness of SB-525 (giroctocogene fitelparvovec), an experimental gene therapy for hemophilia A
• In September 2022, Pfizer and Sangamo Therapeutics announced that the Phase III AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment.
• In November 2021, US Food and Drug Administration (FDA) placed the Pfizer/Sangamo hemophilia A gene therapy program, including the pivotal phase III AFFINE study(NCT04370054), with giroctocogene fitelparvovec (SB-525 or PF07055480), on clinical hold until the review of a proposed protocol amendment.
• In August 2020, Pfizer initiated a a pivotal Phase III study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants with moderately severe or severe hemophilia A (FVIII:C≤1%) for the study duration of 5 years

Route of Administration

Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Hemophilia A Pipeline Therapeutics Assessment

• Hemophilia A Assessment by Product Type
• Hemophilia A By Stage and Product Type
• Hemophilia A Assessment by Route of Administration
• Hemophilia A By Stage and Route of Administration
• Hemophilia A Assessment by Molecule Type
• Hemophilia A by Stage and Molecule Type

DelveInsight’s Hemophilia A Report covers around 40+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Hemophilia A Therapeutics Market include:

Key companies developing therapies for Hemophilia A are – BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.

Emerging Hemophilia A Drugs Under Different Phases of Clinical Development Include:

• Research program: Gene Therapies Generation Bio
• P-FVIII-101: Poseida Therapeutics
• BIVV001: Sanofi in collaboration with Sobi
• Concizumab: Novo Nordisk
• Fitusiran: Sanofi
• ET3 lentiviral gene therapy: Expression Therapeutics
• NXT007: Chugai Pharmaceuticals
• Marstacimab: Pfizer
• ASC618: ASC Therapeutics
• SelectAte: Ascension
• Valrox: BioMarin Pharmaceutical
• STSP-0601: Staidson (Beijing) Biopharmaceutic als
• TQG 203: Chia Tai Tianqing Pharmaceutical Group
• Mim8: Novo Nordisk
• Giroctocogene fitelparvovec: Pfizer

Get a Free Sample PDF Report to know more about Hemophilia A Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020

Hemophilia A Pipeline Analysis:

The Hemophilia A pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.
• Hemophilia A key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia A market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Hemophilia A product details are provided in the report. Download the Hemophilia A pipeline report to learn more about the emerging Hemophilia A therapies

Hemophilia A Pipeline Market Drivers

• Increasing number of hemophilic patients worldwide
• Increasing development of novel therapies
• Increasing diagnostic rate

Hemophilia A Pipeline Market Barriers

• Side effects associated with the plasma derived products
• High cost of recombinant products

Scope of Hemophilia A Pipeline Drug Insight    

• Coverage: Global
• Key Hemophilia A Companies: Gene Therapies Generation Bio, Poseida Therapeutics, Expression Therapeutics, Chugai Pharmaceuticals, ASC Therapeutics, Ascension, Staidson (Beijing) Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Novo Nordisk, Pfizer, and others
• Key Hemophilia A Therapies: Research program, P-FVIII-101, ET3 lentiviral gene therapy, NXT007, ASC618, SelectAte, STSP-0601, TQG 203, Mim8, Giroctocogene fitelparvovec, and others
• Hemophilia A Therapeutic Assessment: Hemophilia A current marketed and Hemophilia A emerging therapies
• Hemophilia A Market Dynamics: Hemophilia A market drivers and Hemophilia A market barriers 

Request for Sample PDF Report for Hemophilia A Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Hemophilia A drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis